TY - JOUR
T1 - MLK4 activates the NF-κB network to drive mesenchymal transition in glioblastoma
AU - Quinn, Leonie M.
AU - Hannan, Ross D.
PY - 2016
Y1 - 2016
N2 - Patients diagnosed with malignant glioma (GBM) face a median survival of just 14 months. The standard care following a GBM diagnosis is an aggressive treatment regime that includes surgery, ionizing radiation (IR), and chemotherapy. These treatment strategies provide only palliation and, following the recurrence of the primary tumour, death ultimately ensues. Treatment decisions for GBM are still made based on WHO tumour grading, despite outcomes varying significantly between subgroups. The identification of molecular prognostic markers to guide treatment and target drug therapies to GBM subtypes is therefore critical for improving patient outcomes.
AB - Patients diagnosed with malignant glioma (GBM) face a median survival of just 14 months. The standard care following a GBM diagnosis is an aggressive treatment regime that includes surgery, ionizing radiation (IR), and chemotherapy. These treatment strategies provide only palliation and, following the recurrence of the primary tumour, death ultimately ensues. Treatment decisions for GBM are still made based on WHO tumour grading, despite outcomes varying significantly between subgroups. The identification of molecular prognostic markers to guide treatment and target drug therapies to GBM subtypes is therefore critical for improving patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85010004893&partnerID=8YFLogxK
U2 - 10.21037/tcr.2016.11.46
DO - 10.21037/tcr.2016.11.46
M3 - Editorial
SN - 2218-676X
VL - 5
SP - S1033-S1038
JO - Translational Cancer Research
JF - Translational Cancer Research
ER -